EU Panel Backs Brentuximab Vedotin for Frontline CD30+ Hodgkin Lymphoma

December 14, 2018 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of brentuximab vedotin for use in combination with chemotherapy as a frontline treatment for adult patients with CD30+ stage IV Hodgkin lymphoma. The CHMP recommendation is based on findings from the phase III ECHELON-1 trial, which demonstrated superior progression-free survival (PFS) with brentuximab vedotin … (leggi tutto)